Advertisement

Drugs & Therapy Perspectives

, Volume 20, Issue 9, pp 1–4 | Cite as

Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis

Drugs and Profile Reports

References

  1. 1.
    Lamb HM, Goa KL. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis Manage Health Outcomes 1999; 6(2): 93–108CrossRefGoogle Scholar
  2. 2.
    Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®): a review of its use in the management of pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63(22): 2501–20PubMedCrossRefGoogle Scholar
  3. 3.
    CHIRON Corporation. TOBI Prescribing Information. Emeryville (CA): CHIRON Corporation, 2001Google Scholar
  4. 4.
    Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls. Infect Dis Clin Pract 1998 Feb; 7(2): 66–79CrossRefGoogle Scholar
  5. 5.
    Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999 Jan 7; 340(1): 23–30PubMedCrossRefGoogle Scholar
  6. 6.
    Ramsey BW, Schaeffler B, Montgomery AB, et al. Survival and lung function during 2 years treatment with intermittent inhaled tobramycin in CF patients [abstract no. 237]. Neth J Med 1998; 54 Suppl. : S83–4CrossRefGoogle Scholar
  7. 7.
    Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002 Sep; 20(3): 658–64PubMedCrossRefGoogle Scholar
  8. 8.
    Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999 May; 179(5): 1190–6PubMedCrossRefGoogle Scholar
  9. 9.
    lies R, Legh-Smith J, Prevost T, et al. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cystic Fibrosis 2003; 2: 120–8CrossRefGoogle Scholar
  10. 10.
    Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 Mar; 167(6): 841–9PubMedCrossRefGoogle Scholar
  11. 11.
    British National Formulary. No. 47. London: The Pharmaceutical Press, Mar 2004Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations